BlackRock Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

BlackRock Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.65M	Buy	57,210 +5,964	+12%	+$158K	﹤0.01%	1599
2016 Q3	$1.63M	Buy	51,246 +1,366	+3%	+$46.3K	﹤0.01%	1566
2016 Q2	$1.62M	Sell	49,880 -106,771	-68%	-$3.57M	﹤0.01%	1534
2016 Q1	$4.38M	Sell	156,651 -167,125	-52%	-$3.64M	﹤0.01%	1147
2015 Q4	$11.5M	Buy	323,776 +5,240	+2%	+$185K	0.01%	756
2015 Q3	$10.5M	Buy	318,536 +20,100	+7%	+$836K	0.01%	758
2015 Q2	$12.5M	Buy	298,436 +215,700	+261%	+$8.35M	0.01%	690
2015 Q1	$2.7M	Buy	82,736 +3,525	+4%	+$121K	﹤0.01%	1119
2014 Q4	$2.52M	Buy	79,211 +3,919	+5%	+$111K	﹤0.01%	1136
2014 Q3	$1.86M	Sell	75,292 -481,144	-86%	-$11.3M	﹤0.01%	1191
2014 Q2	$12.6M	Sell	556,436 -28,105	-5%	-$587K	0.01%	720
2014 Q1	$14.2M	Buy	584,541 +70,122	+14%	+$1.77M	0.01%	665
2013 Q4	$12.9M	Sell	514,419 -550,090	-52%	-$13M	0.01%	711
2013 Q3	$29.2M	Sell	1,064,509 -1,478,400	-58%	-$30.9M	0.03%	465
2013 Q2	$46.2M	Buy	+2,542,909	New	+$35M	0.05%	334

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

BlackRock Advisors's ACAD Position: Q4 2016 in Review

BlackRock Advisors increased its Acadia Pharmaceuticals (ACAD) stake by 12% in Q4 2016, buying an estimated $158K and bringing the position to 57,210 shares worth $1.65M. The position accounts for ﹤0.01% of the portfolio, ranked #1599.

BlackRock Advisors first reported a position in ACAD in Q2 2013 and has held it in 15 quarters since. The position peaked at $46.2M in Q2 2013. 225 funds tracked by Wall St. Rank hold ACAD as of Q4 2016.

BlackRock Advisors held 57,210 shares of Acadia Pharmaceuticals worth $1.65M as of Q4 2016.
BlackRock Advisors bought 5,964 Acadia Pharmaceuticals shares in Q4 2016, an estimated $158K.
Acadia Pharmaceuticals made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #1599 holding.
BlackRock Advisors first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
BlackRock Advisors's Acadia Pharmaceuticals position peaked at $46.2M in Q2 2013.
225 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.